دورية أكاديمية
أعرض في EDS

Chronic Active Antibody-mediated Rejection: Opportunity to Determine the Role of Interleukin-6 Blockade.

التفاصيل البيبلوغرافية
العنوان: Chronic Active Antibody-mediated Rejection: Opportunity to Determine the Role of Interleukin-6 Blockade.
المؤلفون: Berger M; Departments of Pediatrics and Pathology, Case Western Reserve University, Cleveland, OH., Baliker M; Patient Advocate, Middle Town, WI., Van Gelder T; Department Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands., Böhmig GA; Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria., Mannon RB; Division of Nephrology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE., Kumar D; Department of Medicine, Division of Transplant Infectious Disease, Ajmera Transplant Centre, Toronto, ON, Canada., Chadban S; Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia., Nickerson P; Department of Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada., Lee LA; Research and Development, Transplant Therapeutic Area, CSL Behring, King of Prussia, Pennsylvania, PA., Djamali A; Department of Medicine, Maine Medical Center, Portland, ME.
المصدر: Transplantation [Transplantation] 2024 May 01; Vol. 108 (5), pp. 1109-1114. Date of Electronic Publication: 2023 Nov 09.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0132144 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-6080 (Electronic) Linking ISSN: 00411337 NLM ISO Abbreviation: Transplantation Subsets: MEDLINE
أسماء مطبوعة: Publication: Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: Baltimore, Williams & Wilkins.
مواضيع طبية MeSH: Graft Rejection*/immunology , Graft Rejection*/prevention & control , Interleukin-6*/antagonists & inhibitors , Interleukin-6*/immunology , Kidney Transplantation*/adverse effects, Humans ; Chronic Disease ; Antibodies, Monoclonal, Humanized/therapeutic use ; Glomerular Filtration Rate/drug effects ; Immunosuppressive Agents/therapeutic use ; Treatment Outcome ; Isoantibodies/immunology ; Graft Survival/drug effects
مستخلص: Chronic active antibody-mediated rejection (caAMR) is arguably the most important cause of late kidney allograft failure. However, there are no US Food and Drug Administration (FDA)-approved treatments for acute or chronic AMR and there is no consensus on effective treatment. Many trials in transplantation have failed because of slow and/or inadequate enrollment, and no new agent has been approved by the FDA for transplantation in over a decade. Several lines of evidence suggest that interleukin-6 is an important driver of AMR, and clazakizumab, a humanized monoclonal antibody that neutralizes interleukin-6, has shown promising results in phase 2 studies. The IMAGINE trial (Interleukin-6 Blockade Modifying Antibody-mediated Graft Injury and Estimated Glomerular Filtration Rate Decline) (NCT03744910) is the first to be considered by the FDA using a reasonably likely surrogate endpoint (slope of estimated glomerular filtration rate decline >1 y) for accelerated approval and is the only ongoing clinical trial for the treatment of chronic rejection. This trial offers us the opportunity to advance the care for our patients in need, and this article is a call to action for all transplant providers caring for patients with caAMR.
Competing Interests: T.V.G., G.A.B., R.B.M., D.K., S.C., P.N., and A.D. are members of the steering committee for the IMAGINE study and receive consulting fees from CSL Behring. M.Be. received consulting fees from CSL Behring and is a shareholder. L.A.L. is employed by CSL Behring and is a shareholder. The other author declares no conflicts of interest
(Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.)
References: Circulation. 1995 Oct 1;92(7):1866-75. (PMID: 7671371)
Am J Transplant. 2021 Jul;21(7):2413-2423. (PMID: 33382185)
Am J Transplant. 2022 Dec;22 Suppl 4:1-11. (PMID: 36239200)
Kidney Int Rep. 2022 Feb 09;7(4):720-731. (PMID: 35497778)
Am J Transplant. 2014 Feb;14(2):255-71. (PMID: 24401076)
Am J Transplant. 2022 Dec;22 Suppl 4:45-57. (PMID: 36453708)
Am J Transplant. 2013 Apr;13(4):971-983. (PMID: 23414212)
Transplantation. 2020 May;104(5):911-922. (PMID: 31895348)
Am J Transplant. 2021 Aug;21(8):2824-2832. (PMID: 33346917)
Transplantation. 2020 Dec;104(12):2497-2506. (PMID: 32235253)
Physiol Res. 2021 Dec 30;70(Suppl4):S551-S565. (PMID: 35199543)
Am J Transplant. 2021 Apr;21(4):1391-1401. (PMID: 32594646)
Transplantation. 2021 Nov 1;105(11):e156-e167. (PMID: 33724240)
Trials. 2022 Dec 22;23(1):1042. (PMID: 36550562)
Transplantation. 2018 Jun;102(6):e257-e264. (PMID: 29470345)
Eur J Immunol. 1995 May;25(5):1332-7. (PMID: 7774636)
J Immunol. 2015 Mar 15;194(6):2482-5. (PMID: 25681343)
Am J Transplant. 2022 Dec;22 Suppl 4:12-17. (PMID: 36453706)
Nat Rev Immunol. 2023 Oct;23(10):666-681. (PMID: 37069261)
Transplantation. 2021 Mar 1;105(3):648-659. (PMID: 33617203)
Front Immunol. 2022 Apr 14;13:839380. (PMID: 35493469)
Transplantation. 2014 Dec 27;98(12):1262-70. (PMID: 25286051)
Kidney Int. 2021 Aug;100(2):401-414. (PMID: 33675843)
Trials. 2019 Jan 11;20(1):37. (PMID: 30635033)
Am J Transplant. 2020 Jun;20 Suppl 4:12-22. (PMID: 32538535)
Am J Transplant. 2016 May;16(5):1408-20. (PMID: 26614587)
Stroke. 2023 May;54(5):1289-1299. (PMID: 37026458)
Transplantation. 2019 Dec;103(12):2666-2674. (PMID: 30883456)
Am J Transplant. 2018 Apr;18(4):927-935. (PMID: 28949089)
Sci Rep. 2018 Feb 6;8(1):2461. (PMID: 29410442)
Transplant Proc. 2022 Sep;54(7):1809-1815. (PMID: 35907695)
Am J Transplant. 2017 Sep;17(9):2381-2389. (PMID: 28199785)
Am J Transplant. 2016 May;16(5):1350-1. (PMID: 26773799)
Hum Immunol. 2016 Apr;77(4):346-52. (PMID: 26867813)
J Am Soc Nephrol. 2021 Mar;32(3):708-722. (PMID: 33443079)
J Am Soc Nephrol. 2017 Jul;28(7):1991-1996. (PMID: 28232617)
Am J Transplant. 2021 Jul;21(7):2543-2554. (PMID: 33331082)
Am J Transplant. 2020 Sep;20(9):2318-2331. (PMID: 32463180)
Am J Transplant. 2022 Dec;22 Suppl 4:28-37. (PMID: 36453709)
Expert Rev Clin Pharmacol. 2022 May;15(5):575-592. (PMID: 35791866)
J Immunol. 2011 Dec 15;187(12):6268-80. (PMID: 22084439)
Transplantation. 2023 Feb 1;107(2):495-503. (PMID: 35969004)
Clin Transplant. 2021 Jul;35(7):e14320. (PMID: 33864724)
Am J Transplant. 2002 Nov;2(10):970-4. (PMID: 12482151)
J Am Soc Nephrol. 2018 Feb;29(2):591-605. (PMID: 29242250)
Am J Transplant. 2018 Apr;18(4):785-795. (PMID: 29178397)
المشرفين على المادة: 0 (Interleukin-6)
0 (Antibodies, Monoclonal, Humanized)
0 (Immunosuppressive Agents)
0 (Isoantibodies)
تواريخ الأحداث: Date Created: 20231109 Date Completed: 20240425 Latest Revision: 20240426
رمز التحديث: 20240426
مُعرف محوري في PubMed: PMC11042519
DOI: 10.1097/TP.0000000000004822
PMID: 37941113
قاعدة البيانات: MEDLINE
الوصف
تدمد:1534-6080
DOI:10.1097/TP.0000000000004822